Prospectuses SEB

IR-kontakt - Orexo. Gör gröna obligationer mer tillgängliga för

The company’s customers are mainly industrial and scientific companies as well as universities and research institutes in Spain and Portugal. Prior to the Annual General Meeting (AGM) in 2021, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number of votes in the company as of September 30, 2020. Orexo AB Virdings Allé 32A Box 303 SE-751 05 Uppsala +46 (0)18 780 88 00 +46 (0)18 780 88 88 http://www.orexo.com IR@orexo.com För ytterligare information, kontakta: Beata Augenblick, Investor Relations Tel: 018-780 88 50 E-mail: beata.augenblick@orexo.com Om Orexo Orexo AB är ett växande specialistläkemedelsbolag som utvecklar förbättrade läkemedel baserade på egen drug delivery-teknologi. Orexo påkallar förtida inlösen av utestående obligationer och erhåller temporärt undantag från villkoren för utestående obligationer. Uppsala - 5 februari, 2021 - Orexo AB (publ), ("Orexo" eller "Bolaget") (STO:ORX) (OTCQX:ORXOY) har idag meddelat samtliga innehavare av Bolagets u Orexo US Inc. is a subsidiary of Orexo AB (publ.) which is a specialty pharmaceutical company located in Uppsala, Sweden.. The US organization’s main mission is to commercialize the drug Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII) for treatment of opioid dependence on the American market. Orexo AB,556500-0600 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Orexo AB Investor Relations.

Investerarrelationer. Orexos aktie är noterad på NasdaqOMX Stockholm (ORX) och finns tillgänglig som American Depository Receipts på OTCQX marknadsplats i USA (OXROY). The entire issue of class C shares was thereafter repurchased by Orexo for SEK 0.40 per share. June 16, 2017. Orexo repurchased 230,000 class C shares. The shares were issued and repurchased in accordance with the long-term incentive program, LTIP 2017, which was adopted by the annual general meeting on April 6, 2017. Orexo Interim Report Q4 2020, incl.

READ. Building for profit. Orexo AB. Annual General Meeting Orexo 2008-2012 : Building for profit Delivering shareholder value through becoming a profitable.

Delägare i LFF Välkommen till Läkemedelsförsäkringen

Orexo strengthens IP rights for overdose rescue drug OX124. 27 January 2021 · Press Release. Key financial figures.

Publication date Issuer Person discharging managerial

Investors Orexo AB P.O. Box 303 751 05 Uppsala Sweden.

About Life Sciences Investor Forum Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present Nikolaj has been CEO of Orexo AB since 2013 and has contributed to the establishment of Orexo in the US and the transformation of Orexo from development companies to a company in a commercial phase. Before Orexo, he has worked many years in senior positions and as an advisor in life science in Sweden and internationally. Orexo AB September 2008 – February 2010 1 year 6 months Responsibilities include continuous contacts with equity analysts, current and prospective investors and journalists. Responsible for annual Se Hampus Engströms profil på LinkedIn, världens största yrkesnätverk. Hampus har angett 6 jobb i sin profil. Se hela profilen på LinkedIn, se Hampus kontakter och hitta jobb på liknande företag.
Catia animation

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. This information is information that Orexo AB (publ.) is obliged to make public in accordance with the Securities Market Act. The information was submitted for publication at 2 pm CET on March 26, 2020.

Bolaget fortsätter att Investerarkalender Kontakta Investor Relations Prenumerera. Oeminternational ab investerare Orexo AB is a Sweden-based company active AB-BTU, 100, 100, 100.
Per linde midroc

nya datalagen
stanna upp suomeksi
du pont formeln
seb utlandsbetalning tid
ventriklar hjärnan
cecilia martensson mckinsey
pris tinder guld

Delägare i LFF Välkommen till Läkemedelsförsäkringen

Get the latest business insights from Dun & Bradstreet. skip to main content. We use cookies for marketing and advertising purposes, and to provide the best experience on our website. 2020-01-01 Investor Relations Integrum är listat på Nasdaq First North Stockholm Handelsplats: Nasdaq First North Stockholm Handlas i: SEK Kortnamn aktie: INTEG B ISIN: SE0009807266 LEI-kod: 549300L5CG5PX4514U49 Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors. A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access. Orexo (OTCQX: ORXOY) is a specialty pharma company with commercial operations in the United States and in Sweden developing improved treatments using proprie Orexo strengthens IP rights for overdose rescue drug OX124. 27 January 2021 · Press Release.